Source: Annual Congress 2002 - Asthma and COPD: pharmacology
Disease area: Airway diseases

Abstract

We collected all the information about 81 asthmatic and 72 COPD patients in January-February 2002. All of those patients were diagnosed and classified according to international criteria. We found out that 72.8% of asthmatic patients and 76.4% COPD patients were using inhaled long acting beta-2 agonist (LAB2A) medication. Using ratio of LAB2A in mild-moderate-severe persistent asthmatics were 70.8%, 71.4% and 100.0% respectively (p=0.193). In COPD cases these ratios were 73.3%, 71.8 and 88.9% (p=0.309). 84.7% of COPD patients were using inhaled corticosteroids (ICS). Using ratios of ICS in mild-moderate and severe COPD were 66.7%, 89.7% and 88.9% respectively (p=0.128). 68.05% of COPD patients were using LAB2A and ICS synchronously. In asthmatic patients 55.9% were using Salmaterole and 44.1% were using Formoterole, in COPD patients 60.0% were using Salmeterole, 40.0% were using Formoterole as a LAB2A.As an inhalation device for LAB2A in asthmatic patients were 57.6% MDI, 13.6% turbuhaler, 28.8 % discus, and in COPD patients were 78.2% MDI, 5.5% turbuhaler, 9.1% discus and 7.3% inhaler capsule preferred. For ICS, 66.7% MDI, 16.0% turbuhaler, 17.3% discus in asthmatic patients and 80.3% MDI, 8.2% turbuhaler and 11.5% discus in COPD patients were preferred.
Both groups were using LAB2A in high rates. Contrary to our classical information COPD patients were using ICS in high rates.

Rating:

Share or cite this content

Citations should be made in the following way:
C. Sevinc, E. Ceylan, S. Sahbaz, F. Fidan, A. Hayretdag, O. Kilinc, O. Itil, A. H. Cimrin, E. S. Ucan, M. Gok, A. Akkoclu (Izmir, Turkey). Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients. Eur Respir J 2002; 20: Suppl. 38, 753

Member's Comments

No comment yet.

Related content which might interest you: The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006 Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006 Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review Source: Annual Congress 2011 - Asthma management and response Year: 2011 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma Source: Annual Congress 2009 - Epidemiology of atopy and asthma Year: 2009 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017